Methaqualone
NERVOUS SYSTEM
Also known as: cateudyl, melsomin, metaqualon, methaqualon, methaqualoneinone, metolquizolone, quaalude, tuazole, tuazolone
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Methaqualone is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1965. DrugCentral lists 10 molecular targets, including GABRG2|GABRA2|GABRB2, GABRG2|GABRA5|GABRB2 and GABRA1|GABRG2|GABRB3.
- Molecular targets: GABRG2|GABRA2|GABRB2, GABRG2|GABRA5|GABRB2, GABRA1|GABRG2|GABRB3 and GABRD|GABRB3|GABRA6 (10 listed in DrugCentral).
- ATC code: N05CM01 (Other hypnotics and sedatives).
- Molecular formula: C16H14N2O; molecular weight 250.30 g/mol.
Mechanism & targets
Molecular targets (10)
| Target | Gene | Action | Activity |
|---|---|---|---|
| GABA A receptor alpha-2/beta-2/gamma-2 | GABRG2|GABRA2|GABRB2 | positive allosteric modulator | EC50 4.61 |
| GABA A receptor alpha-5/beta-2/gamma-2 | GABRG2|GABRA5|GABRB2 | positive allosteric modulator | EC50 4.56 |
| GABA-A receptor alpha-1/beta-3/gamma-2 | GABRA1|GABRG2|GABRB3 | positive allosteric modulator | EC50 4.52 |
| GABA-A receptor alpha-6/beta-3/delta | GABRD|GABRB3|GABRA6 | positive allosteric modulator | EC50 4.50 |
| GABA-A receptor alpha-6/beta-2/delta | GABRB2|GABRA6|GABRD | positive allosteric modulator | EC50 4.44 |
| GABA-A receptor alpha-1/beta-2/gamma-2 | GABRA1|GABRG2|GABRB2 | positive allosteric modulator | EC50 4.41 |
| GABA A receptor alpha-3/beta-2/gamma-2 | GABRG2|GABRA3|GABRB2 | positive allosteric modulator | EC50 4.31 |
| GABA A receptor alpha-4/beta-2/delta | GABRD|GABRB2|GABRA4 | positive allosteric modulator | EC50 4.17 |
| GABA-A receptor alpha-6/beta-2 | GABRA6|GABRB2 | positive allosteric modulator | EC50 4.13 |
| GABA A receptor alpha-4/beta-3/delta | GABRA4|GABRB3|GABRD | agonist | EC50 3.91 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1965-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N05CM01 | NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Other hypnotics and sedatives |
N05CX02 | NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Hypnotics and sedatives in combination, excl. barbiturates |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Methaqualone is on its molecule page.
| Molecular formula | C16H14N2O |
|---|---|
| Molecular weight | 250.30 g/mol |
| CAS number | — |
| InChIKey | JEYCTXHKTXCGPB-UHFFFAOYSA-N |
| PubChem CID | 6292 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
How does Methaqualone work?
Its molecular targets in DrugCentral include GABRG2|GABRA2|GABRB2 (positive allosteric modulator), GABRG2|GABRA5|GABRB2 (positive allosteric modulator), GABRA1|GABRG2|GABRB3 (positive allosteric modulator) and GABRD|GABRB3|GABRA6 (positive allosteric modulator).
When was Methaqualone first approved?
Methaqualone was first approved by the YEAR INTRODUCED in 1965.
What is the chemical formula of Methaqualone?
Methaqualone has the molecular formula C16H14N2O and a molecular weight of 250.30 g/mol.
Browse: all drugs starting with M · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1739 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL282052 — compound record and bioactivity
- PubChem CID 6292 — chemical identifiers
- DrugBank DB04833 — drug record
- FDA UNII 7ZKH8MQW6T — substance identity
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.